What is Intellia Therapeutics?
Intellia Therapeutics is a genome editing therapeutics company company serving enterprise, commercial, consumer, healthcare, financial, real estate, or regulated-market customers.
- Category
- Genome editing therapeutics company
- Headquarters
- Cambridge, United States
- Founded
- See official company history
- Employees
- See latest annual report and company filings
- Total funding
- Public company
- Status
- Public company; Nasdaq: NTLA
What is Intellia Therapeutics?
Intellia Therapeutics is a genome editing therapeutics company company headquartered in Cambridge, United States. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
Intellia Therapeutics is a genome editing therapeutics company company headquartered in Cambridge, United States. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
For sellers, Intellia Therapeutics should be mapped as a scaled public-company account. The best timing signals are earnings commentary, capital spending, hiring clusters, product launches, acquisitions, facility investments, and leadership changes.
What does Intellia Therapeutics offer?
Intellia Therapeutics's profile centers on Genome editing, In vivo therapies, Ex vivo therapies, Rare diseases.
- Genome editing· Genome editing therapeutics company
- In vivo therapies· Genome editing therapeutics company
- Ex vivo therapies· Genome editing therapeutics company
- Rare diseases· Genome editing therapeutics company
- Clinical development· Genome editing therapeutics company
- CRISPR platform· Genome editing therapeutics company
How does Intellia Therapeutics make money?
Intellia Therapeutics makes money through commercial activity tied to genome editing therapeutics company.
Intellia Therapeutics monetizes through the model common to genome editing therapeutics company: product sales, recurring services, contracts, leases, subscriptions, transaction volume, servicing, investment management, or usage depending on the operating unit.
Sales angles should connect to measurable priorities such as margin, growth, occupancy, compliance, retention, automation, risk reduction, data quality, customer experience, or field productivity.
Who leads Intellia Therapeutics?
Intellia Therapeutics's named executives should be verified on the official leadership or investor-relations page before outreach.
- Intellia Therapeutics executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Intellia Therapeutics finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, capital allocation, and budget discipline.
- Intellia Therapeutics operations or technology leadershipOperations, product, technology, security, or commercial leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operating-improvement purchases.
How do you contact Intellia Therapeutics's leadership?
Intellia Therapeutics should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.intelliatx.com- Intellia Therapeutics investor relationsInvestor relations / corporate contactcontact via https://www.intelliatx.com
- Intellia Therapeutics sales or partnershipsCommercial contact routecontact via https://www.intelliatx.com
- Intellia Therapeutics media relationsMedia or communications contact routecontact via https://www.intelliatx.com
How is Intellia Therapeutics funded?
Intellia Therapeutics's current status is Public company; Nasdaq: NTLA.
Intellia Therapeutics's capital profile is best understood through its current public-company status: Public company; Nasdaq: NTLA. For public companies, financing and budget signals are usually found in annual reports, quarterly results, debt disclosures, buybacks, acquisitions, capital expenditure plans, and management commentary rather than venture funding rounds.
Before outreach, verify the latest status on the company's investor-relations page and current exchange filings.
How did Intellia Therapeutics get here?
Intellia Therapeutics's history should be read through founding, scale-up, public-market ownership, and current product or market focus.
- FoundingIntellia Therapeutics is foundedThe company begins building in genome editing therapeutics company.
- Scale-upCommercial footprint expandsIntellia Therapeutics broadens its product, customer, distribution, or geographic reach.
- Public marketsPublic company; Nasdaq: NTLAPublic-company ownership shapes reporting, procurement, and operating priorities.
- 2025Scaled operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, public-company status, and source references.
Who are Intellia Therapeutics's competitors?
Intellia Therapeutics competes with larger incumbents and focused specialists in genome editing therapeutics company.
Intellia Therapeutics — frequently asked questions
